Sinopharm Group
Market Cap
HK$58.0b
Last Updated
2021/01/16 10:35 UTC
Data Sources
Company Financials +
Executive Summary
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Very undervalued established dividend payer.
Similar Companies
Share Price & News
How has Sinopharm Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1099 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 1099's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
1.3%
1099
-3.3%
HK Healthcare
2.2%
HK Market
1 Year Return
-36.0%
1099
-18.2%
HK Healthcare
7.2%
HK Market
Return vs Industry: 1099 underperformed the Hong Kong Healthcare industry which returned -17.9% over the past year.
Return vs Market: 1099 underperformed the Hong Kong Market which returned 7.5% over the past year.
Shareholder returns
| 1099 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.3% | -3.3% | 2.2% |
| 30 Day | 0.1% | -0.2% | 8.4% |
| 90 Day | 15.8% | 14.9% | 15.6% |
| 1 Year | -33.8%-36.0% | -16.0%-18.2% | 11.4%7.2% |
| 3 Year | -40.3%-45.0% | -42.8%-46.4% | -3.4%-13.5% |
| 5 Year | -24.9%-32.8% | -29.9%-32.0% | 65.4%37.4% |
Long-Term Price Volatility Vs. Market
How volatile is Sinopharm Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?3 weeks ago | Simply Wall St
What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?1 month ago | Simply Wall St
Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) SharesValuation
Is Sinopharm Group undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1099 (HK$18.62) is trading below our estimate of fair value (HK$89.83)
Significantly Below Fair Value: 1099 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1099 is good value based on its PE Ratio (7x) compared to the HK Healthcare industry average (20.6x).
PE vs Market: 1099 is good value based on its PE Ratio (7x) compared to the Hong Kong market (11.5x).
Price to Earnings Growth Ratio
PEG Ratio: 1099 is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: 1099 is good value based on its PB Ratio (0.8x) compared to the HK Healthcare industry average (1.5x).
Next Steps
Future Growth
How is Sinopharm Group forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
9.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1099's forecast earnings growth (9.5% per year) is above the savings rate (1.5%).
Earnings vs Market: 1099's earnings (9.5% per year) are forecast to grow slower than the Hong Kong market (21% per year).
High Growth Earnings: 1099's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1099's revenue (8.3% per year) is forecast to grow slower than the Hong Kong market (14.1% per year).
High Growth Revenue: 1099's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1099's Return on Equity is forecast to be low in 3 years time (13.5%).
Next Steps
Past Performance
How has Sinopharm Group performed over the past 5 years?
11.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1099 has high quality earnings.
Growing Profit Margin: 1099's current net profit margins (1.5%) are lower than last year (1.6%).
Past Earnings Growth Analysis
Earnings Trend: 1099's earnings have grown by 11% per year over the past 5 years.
Accelerating Growth: 1099's earnings growth over the past year (4.8%) is below its 5-year average (11% per year).
Earnings vs Industry: 1099 earnings growth over the past year (4.8%) exceeded the Healthcare industry -9.1%.
Return on Equity
High ROE: 1099's Return on Equity (13.1%) is considered low.
Next Steps
Financial Health
How is Sinopharm Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1099's short term assets (CN¥280.7B) exceed its short term liabilities (CN¥219.7B).
Long Term Liabilities: 1099's short term assets (CN¥280.7B) exceed its long term liabilities (CN¥18.2B).
Debt to Equity History and Analysis
Debt Level: 1099's debt to equity ratio (75.9%) is considered high.
Reducing Debt: 1099's debt to equity ratio has increased from 70.9% to 75.9% over the past 5 years.
Debt Coverage: 1099's debt is not well covered by operating cash flow (12.3%).
Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (7.3x coverage).
Balance Sheet
Next Steps
Dividend
What is Sinopharm Group current dividend yield, its reliability and sustainability?
3.86%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1099's dividend (3.86%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.13%).
High Dividend: 1099's dividend (3.86%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.66%).
Stability and Growth of Payments
Stable Dividend: 1099's dividends per share have been stable in the past 10 years.
Growing Dividend: 1099's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27.1%), 1099's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1099's dividends in 3 years are forecast to be well covered by earnings (27.4% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.3yrs
Average management tenure
CEO
Yong Liu (51 yo)
3.17yrs
Tenure
CN¥7,447,000
Compensation
Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm...
CEO Compensation Analysis
Compensation vs Market: Yong's total compensation ($USD1.15M) is above average for companies of similar size in the Hong Kong market ($USD438.23K).
Compensation vs Earnings: Yong's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting Executive Chairman o the Board | no data | CN¥3.47m | 0.0032% CN¥ 1.9m | |
| President & Executive Director | 3.17yrs | CN¥7.45m | 0.0022% CN¥ 1.3m | |
| CFO & Vice President | 10.67yrs | no data | no data | |
| Joint Company Secretary | 9.42yrs | no data | no data | |
| Joint Company Secretary | 2.08yrs | no data | no data | |
| Vice President | no data | no data | no data | |
| Non-Executive Vice President | 9.83yrs | no data | no data | |
| Vice President | 10.33yrs | no data | no data | |
| Vice President | 3yrs | no data | no data | |
| Vice President | 3yrs | no data | no data |
6.3yrs
Average Tenure
51yo
Average Age
Experienced Management: 1099's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting Executive Chairman o the Board | no data | CN¥3.47m | 0.0032% CN¥ 1.9m | |
| President & Executive Director | 3.17yrs | CN¥7.45m | 0.0022% CN¥ 1.3m | |
| Non-Executive Director | 4.25yrs | no data | no data | |
| Non-Executive Vice Chairman | 7.17yrs | no data | no data | |
| Independent Non-Executive Director | 4.83yrs | CN¥300.00k | no data | |
| Non-Executive Director | 13.42yrs | no data | no data | |
| Independent Non-Executive Director | 0.33yr | no data | no data | |
| Independent Non-Executive Director | 0.33yr | no data | no data | |
| Non-Executive Director | 3.33yrs | no data | no data | |
| Non-Executive Director | 2.25yrs | no data | no data | |
| Independent Non-Executive Director | 0.33yr | no data | no data | |
| Chief Supervisor | 0.33yr | no data | no data |
3.1yrs
Average Tenure
55yo
Average Age
Experienced Board: 1099's board of directors are considered experienced (3.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.
Top Shareholders
Company Information
Sinopharm Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sinopharm Group Co., Ltd.
- Ticker: 1099
- Exchange: SEHK
- Founded: 2003
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: HK$58.032b
- Shares outstanding: 3.12b
- Website: https://www.sinopharmgroup.com.cn
Number of Employees
Location
- Sinopharm Group Co., Ltd.
- Sinopharm Plaza
- No. 1001 Zhongshan Road (West)
- Shanghai
- Shanghai Province
- 200051
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1099 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| SHTD.F | OTCPK (Pink Sheets LLC) | Yes | Foreign Shares-Foreign Listed | US | USD | Sep 2009 |
| X2S | DB (Deutsche Boerse AG) | Yes | Foreign Shares-Foreign Listed | DE | EUR | Sep 2009 |
| 1099 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| 1099 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| SHTD.Y | OTCPK (Pink Sheets LLC) | UNSP ADR EACH REP 5 ORD SHS | US | USD | Aug 2012 | |
| X2S1 | DB (Deutsche Boerse AG) | UNSP ADR EACH REP 5 ORD SHS | DE | EUR | Aug 2012 |
Biography
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. Its Pharmaceutical Distribution se...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/16 10:35 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.